NCT07506499

Brief Summary

Heart failure is a common clinical condition that often leads to reduced exercise tolerance, shortness of breath, and poor quality of life. Many patients with heart failure also develop weakness of the inspiratory muscles, which contributes to limited physical activity and worsening functional capacity. Inspiratory muscle training (IMT) has been suggested as a useful rehabilitation method to improve respiratory muscle strength and exercise tolerance. In addition, functional electrical stimulation (FES) of the lower limb muscles may help activate skeletal muscles and improve functional performance in patients who cannot tolerate conventional exercise. This randomized controlled study aims to investigate the effect of combining inspiratory muscle training with functional electrical stimulation of the lower limbs in patients with decompensated heart failure. A total of 135 hospitalized patients with decompensated heart failure will be recruited from the Cardiology Department at Beni-Suef University Hospital and randomly assigned into three groups. Group A (45 patients) will receive routine medical treatment in addition to inspiratory muscle training combined with functional electrical stimulation. Group B (45 patients) will receive routine medical treatment with inspiratory muscle training only. Group C (45 patients) will receive routine medical treatment alone. The intervention will start during hospitalization and will continue for four weeks. The study will evaluate the effects of these interventions on cardiac function, inspiratory muscle strength, and functional capacity as primary outcomes. Secondary outcomes will include dyspnea severity, quality of life, heart rate, oxygen saturation, hand grip strength, and maximum expiratory pressure. The findings of this study may help clarify the potential role of combining inspiratory muscle training with functional electrical stimulation as part of cardiac rehabilitation in patients with decompensated heart failure.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
135

participants targeted

Target at P50-P75 for not_applicable

Timeline
1mo left

Started Apr 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Apr 2026Jul 2026

First Submitted

Initial submission to the registry

March 5, 2026

Completed
27 days until next milestone

First Posted

Study publicly available on registry

April 1, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2026

Expected
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2026

Last Updated

April 15, 2026

Status Verified

April 1, 2026

Enrollment Period

3 months

First QC Date

March 5, 2026

Last Update Submit

April 10, 2026

Conditions

Outcome Measures

Primary Outcomes (3)

  • Cardiac Function (Ejection Fraction)

    Cardiac function will be assessed using echocardiography to measure left ventricular ejection fraction.

    Baseline and 4 weeks

  • Maximum Inspiratory Pressure

    Inspiratory muscle strength will be assessed by measuring maximum inspiratory pressure (MIP) using a maximum inspiratory pressure meter.

    Baseline and 4 weeks

  • Functional capacity (6-minute walk test)

    Functional capacity will be assessed using the 6-minute walk test (6MWT) by measuring the distance walked in meters.

    Baseline and 4 weeks

Secondary Outcomes (8)

  • Dyspnea Severity

    Baseline and 4 weeks

  • Quality of Life (Minnesota Living with Heart Failure Questionnaire Score)

    Baseline and 4 weeks

  • Heart Rate

    Baseline and 4 weeks

  • Hand Grip Strength

    Baseline and 4 weeks

  • Maximum Expiratory Pressure

    Baseline and 4 weeks

  • +3 more secondary outcomes

Study Arms (3)

IMT + FES Group

EXPERIMENTAL

Participants receive routine medical treatment combined with inspiratory muscle training and functional electrical stimulation of the lower limb muscles as part of a cardiac rehabilitation program.

Device: Inspiratory Muscle TrainerDevice: Functional Electrical StimulationOther: Standard medical treatment

IMT Group

ACTIVE COMPARATOR

Participants receive routine medical treatment combined with inspiratory muscle training.

Device: Inspiratory Muscle TrainerOther: Standard medical treatment

Control Group

ACTIVE COMPARATOR

Participants receive routine medical treatment only.

Other: Standard medical treatment

Interventions

Inspiratory muscle training performed using a threshold inspiratory muscle trainer at 30% of maximal inspiratory pressure for 30 minutes per session, 4-5 sessions per week for four weeks.

IMT + FES GroupIMT Group

Functional electrical stimulation will be applied to the quadriceps and gastrocnemius muscles of both lower limbs using surface electrodes. Electrical stimulation will be delivered at a frequency of 10 Hz, pulse width of 150 ms, and 20 seconds on / 20 seconds off duty cycle for approximately 45 minutes per session.

IMT + FES Group

Participants will receive routine pharmacological treatment for heart failure according to hospital guidelines.

Control GroupIMT + FES GroupIMT Group

Eligibility Criteria

Age45 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged from 45 to 65 years old
  • Both sexes
  • Hospitalized heart failure patients with ejection fraction \< 40%
  • Conscious and cooperative
  • Able to participate in training actively

You may not qualify if:

  • Acute major cardiovascular events (e.g., acute coronary syndrome, stroke, or pulmonary embolism)
  • Uncontrolled life-threatening arrhythmias
  • Severe valvular heart disease requiring urgent surgery
  • Pregnancy
  • End-stage renal disease requiring dialysis
  • Significant pulmonary diseases such as pulmonary arterial hypertension,
  • Implanted pacemaker
  • Clinically significant peripheral vascular disease
  • Severe anemia
  • Exercise-induced angina or ST-segment changes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beni-Suef University Hospital

Banī Suwayf, Beni-Suef Governorate, Egypt

RECRUITING

Study Officials

  • SHERIN HASSAN MEHANI, Professor of Physical Therapy

    Faculty Of Physical Therapy Beni-Suef University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Salma mostafa Elsalhy, BSc

CONTACT

MAHMOUD IBRAHIM MOHAMED, PT, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Teaching Assistant

Study Record Dates

First Submitted

March 5, 2026

First Posted

April 1, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

June 15, 2026

Study Completion (Estimated)

July 1, 2026

Last Updated

April 15, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations